Table 2 Cox proportional hazards regression analysis of factors associated with overall survival of glioma patients
Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | |
MGMT | 0.37 (0.30–0.46) | 6.81 × 10−19 | 0.98 (0.75–1.28) | 0.88 |
IDH mutation vs wild | 0.13 (0.10–0.17) | 6.05 × 10−51 | 0.40 (0.26–0.63 | 6.40 × 10− 5 |
Grade III vs Grade II | 3.20 (1.93–5.29) | 5.86 × 10−6 | 2.44 (1.44–4.12) | 9.34 × 10−4 |
Grade IV vs Grade II | 14.28 (9.14–22.32) | 1.88 × 10− 31 | 5.02 (2.70–9.36) | 3.71 × 10−6 |
Age | 1.06 (1.05–1.06) | 7.91 × 10−58 | 1.05 (1.03–1.06) | 3.85 × 10− 15 |
Gender | 1.13 (0.94–1.35) | 0.19 | 1.51 (1.17–1.93) | 0.014 |
ATG2A mRNA | 0.41 (0.35–0.48) | 2.95 × 10− 30 | 1.17 (0.79–1.73) | 0.43 |
ATG2B mRNA | 0.47 (0.40–0.54) | 4.50 × 10−24 | 0.98 (0.75–1.27) | 0.86 |
ATG3 mRNA | 1.42 (1.10–1.84) | 0.008 | 0.63 (0.40–0.99) | 0.05 |
ATG4A mRNA | 2.37 (2.02–2.79) | 1.04 × 10− 25 | 0.90 (0.64–1.28) | 0.56 |
ATG4C mRNA | 1.48 (1.27–1.73) | 9.91 × 10− 7 | 1.54 (1.16–2.01) | 3 × 10− 3 |
ATG5 mRNA | 1.74 (1.43–2.13) | 4.32 × 10− 8 | 0.61 (0.43–0.86) | 5 × 10−3 |
ATG7 mRNA | 2.32 (1.89–2.86) | 1.66 × 10− 15 | 1.36 (0.94–1.98) | 0.1 |
ATG9A mRNA | 0.42 (0.34–0.51) | 7.05 × 10− 17 | 0.74 (0.49–1.13) | 0.16 |
ATG9B mRNA | 1.44 (1.33–1.57) | 1.57 × 10− 18 | 0.97 (0.88–1.07) | 0.52 |
ATG10 mRNA | 2.18 (1.86–2.55) | 1.08 × 10− 21 | 1.11 (0.82–1.41) | 0.50 |
ATG12 mRNA | 2.05 (1.62–2.61) | 4.59 × 10− 9 | 0.998 (0.66–1.52) | 0.99 |
ATG16L1 mRNA | 3.17 (2.53–3.97) | 8.53 × 10−24 | 1.01 (0.77–1.09) | 0.96 |
ATG16L2 mRNA | 0.78 (0.70–0.88) | 7.22 × 10−5 | 0.92 (0.77–1.09) | 0.34 |